{"name":"WuXi Biologics","slug":"wuxi-bio","ticker":"2269.HK","exchange":"HKEX","domain":"wuxibiologics.com","description":"WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.","hq":"Wuxi, China","founded":0,"employees":"13252","ceo":"Chris Chen","sector":"Biologics CDMO","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":32.64,"stockChange":-1.22,"stockChangePercent":-3.6,"marketCap":"$19.9B","metrics":{"revenue":3211451352.786719,"revenueGrowth":17.2,"grossMargin":46,"rdSpend":0,"netIncome":723400247.2726476,"cash":2318722251.596032,"dividendYield":0,"peRatio":24.4,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Rituximab patent cliff ($1.5B at risk)","drug":"Rituximab","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Trastuzumab patent cliff ($2.2B at risk)","drug":"Trastuzumab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-08-16","type":"earnings","headline":"WuXi Biologics Reports Strong Second-Quarter 2024 Results","summary":"WuXi Biologics reported strong second-quarter 2024 results, with revenue increasing 25% year-over-year. The company's net income also rose 30% year-over-year.","drugName":"","sentiment":"positive"},{"date":"2024-06-01","type":"deal","headline":"WuXi Biologics Partners with Biogen to Develop and Manufacture Biologics","summary":"WuXi Biologics has partnered with Biogen to develop and manufacture biologics for various therapeutic areas. The partnership aims to accelerate the development and commercialization of biologics products.","drugName":"","sentiment":"neutral"},{"date":"2024-03-15","type":"regulatory","headline":"WuXi Biologics Receives FDA Approval for New Manufacturing Facility","summary":"WuXi Biologics has received FDA approval for its new manufacturing facility in China. The facility will support the company's growing demand for biologics manufacturing services.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPZ2wxYnhsRGx5Nzd5bGVYQ2R0RzBQSFdmZS03S2QzQm1ndzZYR3FGSVV5a0x5NVY3Si1VVVo0a0hKdGl4YTZ4clNXa1VVSDZYX0poaTY3MUg3YnBnNWZNd3RDMEtsUWhwdnQ1emdjNVNkY2FJY2ZiZktoZ1BIMEVPeXFpbzlrenFVMlRnQUZjNGRtZndNdXNaU21XY01JeEZvcEF4TWZNZDZONHVHRmtlZ3RBakdtVG1hVWdtWTMxb0FreGlGTEZ4S2Zfb3BEcmNST0J2UG9LeW4?oc=5","date":"2026-02-04","type":"deal","source":"BioPharma APAC","summary":"WuXi Biologics Partners With Vertex To Advance Trispecific T Cell Engager For Autoimmune Diseases - BioPharma APAC","headline":"WuXi Biologics Partners With Vertex To Advance Trispecific T Cell Engager For Autoimmune Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQd25aeEJKcEhjT2tvaVJOblcyREhISFBQYkJ3bHRBRGRNU2JvXzMwVUdtY2hVN3FaczlXWmUxRGNab1lmbnFfX2xlMDRLSjBxVmxUbVA1aXFYQUx6VFBzTGNQS1RLdldoNUR4STdZamdLM1hnN1phVmJiUVRsRU5TR3N5WVJ1ODRucVIxWVB4d2Y2anpkcTZjWmJLM1FHYnYtd2FtXw?oc=5","date":"2026-01-16","type":"pipeline","source":"The Pharma Letter","summary":"Chinese CDMO seeks to consolidate leadership in ADC space - The Pharma Letter","headline":"Chinese CDMO seeks to consolidate leadership in ADC space","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSGZNeEhaNTkyd1NSVVpUNjJqNTE2Y0wxUV9WWnVucktHTmtma2ZjbUFwTnAwUjFJOU8wX05zU2RaSE0tWWFrWkRGdFluWV9mdTliTFo4OVg0OVlPTmZEUDJyenVpWmV3RWRldjU5M01MODFvSDFKV3U2alh2RVVna21qUmdudWM5VFB2ZE9PNFQwYkwzSFBqWXVnNy1wYnlHNDVPRlNSUC1Kc0JmZS00enJWRG8zekVyVENr?oc=5","date":"2025-09-18","type":"pipeline","source":"BioPharma APAC","summary":"WuXi Biologics Secures First Turkish GMP Certification for Three Facilities - BioPharma APAC","headline":"WuXi Biologics Secures First Turkish GMP Certification for Three Facilities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxPSHhkNlVTRlU3SkU5U1NYUmRHaDdUY21QaERVdzhFV2pxbGlnSHNjTzlZZDVZclk2Qk9SS2tQX0Nlb3RlQTZzSnR3a2ktN1JQd2Q0YW16RnRHbnEtS21PZVVmZjFLSFJ2MzdFa3VwMmlRelo1TmFUa3RCTFVkeTBENmhMTkU5Sl9ON0FDQmFfUHU5NmtOQ0ZKOWVsU3ZLR3c1ZFVXRDY3TXVvaW5DMzBka2VINVpRMlBtSUJ4bTZJQzVxWXQxZDVjbEYyQUd1dVV4NkxuQWRQNkhwNDFXQXRLT0JmZ3ViWE1Mamh2NGxYME4?oc=5","date":"2025-08-13","type":"pipeline","source":"BioPharma APAC","summary":"WuXi Biologics Achieves Fully Automated Continuous Drug Substance Manufacturing at Pilot Scale with WuXiUP™ Platform - BioPharma APAC","headline":"WuXi Biologics Achieves Fully Automated Continuous Drug Substance Manufacturing at Pilot Scale with WuXiUP™ Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOMkQtUHY2YnpjQlF2RUk2RXJhWmFyY1hSWUEzZmhCUkt6WlljbDBSYWoxRDdoTlhDRW9SUWkxU0N1VFVsOTN5WGVTUzRTVDh3WmpYTFkzWjFrTm45TGlzTUFEaDlCTGRPeTdPWDFMdlBlTzQ3Ylo4d213Mkc1YjdsNW92bzJxbHVEWktaVWZRc3VtOUd0Q0E?oc=5","date":"2025-07-31","type":"earnings","source":"thebambooworks.com","summary":"Rising profit at WuXi Biologics underscores drug sector rebound - thebambooworks.com","headline":"Rising profit at WuXi Biologics underscores drug sector rebound","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPaTZHX1g0Rl9ocGxnQWQ2UEJFTUpPRnMzUEp6aS1IdHlrQzgySmdPUXlzdWVBSDhzWVNpQTVFRzNZSXpScV9TazBGODFJT082cWpsQ3Jyd0dSb0V3YzQwTUVlczczRzJzbGh2ZXZWR1JyNTl2YWpyR2kxWDZUR29Wd3lEMHdnUUw4Vk1YakttVUQ4dmtoUUF5UHNDWmIzcWJITndGaThHYXRBcGNmUldhU0xmY1VJNC14aEV4czk5ekV1YW5hS3Q1RjV5MnRzOEQ1aHIyWUVRQUZ4b1hVeXU0RGNocVVweF9Ga0J6UGFBZ1BhM0dM?oc=5","date":"2025-07-30","type":"pipeline","source":"BioPharma APAC","summary":"WuXi Biologics Begins Construction of One of the World’s Largest Modular Biologics Drug Product Facilities in Singapore - BioPharma APAC","headline":"WuXi Biologics Begins Construction of One of the World’s Largest Modular Biologics Drug Product Facilities in Singapore","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNN1BhdWpMNEJtSkNJRTZydmxQallpU3ZFTUhqQkRaNVQ0NHBRQkRjTkZWRXJSc21WcmRvY1Z4aXRxOFZ6NGE1enVBSERNZjJwc3llUU9jbnpmZ3gwZTZBV3JYcjV3dy1oVWxYV1dFZ0xiYURRVFNJa25ST2Qzb0xKVTByMmpuNVQ1SXY4Z0p4bWtrMy1MeDRNZUpmSQ?oc=5","date":"2025-07-22","type":"regulatory","source":"BioPharma APAC","summary":"WuXi Biologics China PFS Site Clears FDA Inspection - BioPharma APAC","headline":"WuXi Biologics China PFS Site Clears FDA Inspection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPdndkelh1ZDEwcjF6MXNkRFBCSUdpWFM3ckJzQmMtRkNYalRmc0d0Uzl2bFNWQ0NnVGtIYUtWMzRuX3AzOG5QRUxDazZSLVJLZlZHUEFqWmxhMkRmMUdMM3BaWXdzS0ZiclA1M2dfa2VzdU10X0Nfb1cyakp2TEtucV9zc1g3eGQxOHVaMGFpQlFrbFZHQnFlRTZPaTNtbWtSb3Fsdk9KNnFQSzlCRUJjaklrTUxfanRWb3lKdjZNS1c?oc=5","date":"2025-06-17","type":"pipeline","source":"Reuters","summary":"China pharma projects disrupted by Sino-US tensions - Reuters","headline":"China pharma projects disrupted by Sino-US tensions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQUl9naTJpZnkyLWdhbEgwTEhGb0N1YnZMTDA5MEQtMDRta2lTOEg4RjFtRElxcGN3Q2xIVDZGOHR6S256MUFJQ0FrS0tyVkhacHFOMkktaXpwTGZwWEhqekxtYllGOGlfQUFMLThpaDVYRGpRcHJ6UUFlVU1NeEFkMXpNY21KemFINXVPZWlHOVJKU0I3THpVQUQ4WGMxRjNNM2xlV2pSQjhuVkVzdlRIdQ?oc=5","date":"2025-01-14","type":"pipeline","source":"Yicai Global","summary":"China’s WuXi AppTec Jumps After Banking USD312 Million From Latest Asset Sale - Yicai Global","headline":"China’s WuXi AppTec Jumps After Banking USD312 Million From Latest Asset Sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQWmJvb3BUSkZreHNwakd0RkFNZ0EwR2ZxbUF2aHE2VjdON1RzVHNPcE1qRldmT2IyWFhyX0xTeFRoUHBPald0aWdNNUIwOE9BZjVrb3JRbHVTMEs4Tkc3VlVvbHFsd1FnUDgxeVRwMWdZemJ6ZUU2blNNUFhMV1Y4d0xseHFGUlRkRGd1c19uY3lBelFiR09Jb2xYemUwdmZrVnJ6d3hwZG1nMkZjVXg0MmtZamRNbkFTSVEwanZwU2tCaEViXzRjZnRLQlk?oc=5","date":"2023-06-27","type":"deal","source":"PR Newswire","summary":"Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership - PR Newswire","headline":"Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNV2dWeENMcnVkZENiRFR3TExBRFVQaVotcVlXZnRpaTg1RXY0X09BckpTdjh4YjczdzN3ZzlCdHVmX1JGTUVoUl9SeUhVR0RKX2RUOV9WbnFtYmpxakRWR1RhUTI4TUJIRzdmYTljSWVidUxaNTdRTlYzZ1RNWGJiLVdBbFZ6V3RYWERha3dyVFhMTTVlcEdV?oc=5","date":"2023-04-14","type":"pipeline","source":"thebambooworks.com","summary":"Fast-growing Duoning Biotech seeks winning formula for pricey IPO - thebambooworks.com","headline":"Fast-growing Duoning Biotech seeks winning formula for pricey IPO","sentiment":"neutral"}],"patents":[{"drugName":"Rituximab","drugSlug":"rituximab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Trastuzumab","drugSlug":"trastuzumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":2200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Catalent","Lonza","Pfizer CenterChem"],"therapeuticFocus":["Oncology","Immunology","Infectious Diseases"],"financials":{"source":"yahoo_finance","revenue":3211451421.1718597,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":3211451421.1718597},{"period":"2024-12-31","value":2752409233.38667},{"period":"2023-12-31","value":2510538652.53135},{"period":"2022-12-31","value":2250322136.3282}],"grossProfit":1476546031.32624,"grossProfitHistory":[{"period":"2025-12-31","value":1476546031.32624},{"period":"2024-12-31","value":1127591393.5514},{"period":"2023-12-31","value":1006308134.7647699},{"period":"2022-12-31","value":990997084.82478}],"rdSpend":125771770.59198,"rdSpendHistory":[{"period":"2025-12-31","value":125771770.59198},{"period":"2024-12-31","value":112959725.94410999},{"period":"2023-12-31","value":115815837.26494},{"period":"2022-12-31","value":100634925.42785999}],"sgaSpend":340939132.83162,"operatingIncome":1040057970.56769,"operatingIncomeHistory":[{"period":"2025-12-31","value":1040057970.56769},{"period":"2024-12-31","value":733048037.15308},{"period":"2023-12-31","value":655877910.7086899},{"period":"2022-12-31","value":707190052.98835}],"netIncome":723400279.10711,"netIncomeHistory":[{"period":"2025-12-31","value":723400279.10711},{"period":"2024-12-31","value":494625158.04337},{"period":"2023-12-31","value":501058077.54033},{"period":"2022-12-31","value":651469574.58622}],"eps":1.16,"epsHistory":[{"period":"2025-12-31","value":1.16},{"period":"2024-12-31","value":0.78},{"period":"2023-12-31","value":0.77},{"period":"2022-12-31","value":1.01}],"cash":1357944089.08122,"cashHistory":[{"period":"2025-12-31","value":1357944089.08122},{"period":"2024-12-31","value":1220200497.31214},{"period":"2023-12-31","value":1425157987.43503},{"period":"2022-12-31","value":942539137.9029399}],"totalAssets":9387737989.66626,"totalLiabilities":1570705591.30738,"totalDebt":457482741.27682,"equity":6963593499.03652,"operatingCashflow":934536307.79194,"operatingCashflowHistory":[{"period":"2025-12-31","value":934536307.79194},{"period":"2024-12-31","value":768928571.20489},{"period":"2023-12-31","value":687935656.4102399},{"period":"2022-12-31","value":816741575.50121}],"capex":-550576878.4426299,"capexHistory":[{"period":"2025-12-31","value":-550576878.4426299},{"period":"2024-12-31","value":-579154498.40917},{"period":"2023-12-31","value":-623500641.32978},{"period":"2022-12-31","value":-864893705.2502999}],"freeCashflow":383959429.34931,"dividendsPaid":null,"buybacks":-232434610.41283998,"employees":13252,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":32.64,"previousClose":33.86,"fiftyTwoWeekHigh":44,"fiftyTwoWeekLow":22.95,"fiftyTwoWeekRange":"22.95 - 44.0","fiftyDayAverage":34.5,"twoHundredDayAverage":35.35,"beta":0.58,"enterpriseValue":18876950940.76154,"forwardPE":16.6,"priceToBook":2.48,"priceToSales":6.19,"enterpriseToRevenue":5.88,"enterpriseToEbitda":16.16,"pegRatio":1.07,"ebitda":1167938452.4065843,"ebitdaMargin":36.4,"freeCashflow":631394104.7350067,"operatingCashflow":934536286.5689651,"totalDebt":457482748.35114497,"debtToEquity":5.9,"currentRatio":3.39,"returnOnAssets":6.9,"returnOnEquity":11.6,"analystRating":"","recommendationKey":"none","numberOfAnalysts":21,"targetMeanPrice":46.31,"targetHighPrice":78.21,"targetLowPrice":30.5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":10,"institutionHeldPercent":35.9,"sharesOutstanding":4133579013,"floatShares":3735143332,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":1.34,"epsForward":1.96,"revenuePerShare":5.41,"bookValue":13.17,"officers":[{"age":58,"name":"Dr. Ge  Li Ph.D.","title":"Founder & Chairman"},{"age":52,"name":"Dr. Zhisheng  Chen Ph.D.","title":"CEO & Executive Director"},{"age":54,"name":"Dr. Xuejun  Gu Ph.D.","title":"CTO, Executive VP of Global Biologics Development Department & Executive Director"},{"age":56,"name":"Mr. Ming  Tu","title":"CFO & Executive VP"},{"age":null,"name":"Lihua  Yu M.B.A.","title":"COO & Senior VP"},{"age":59,"name":"Dr. Jijie  Gu Ph.D.","title":"Chief Scientific Officer & President of Global Biologics Research"},{"age":null,"name":"Ms. Lina  Fan Ph.D.","title":"Senior VP & Head of Investor Relations"},{"age":null,"name":"He  Wang","title":"General Counsel, Chief Compliance Officer, SVP and Head of Legal & Compliance Department"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.wuxibiologics.com","phone":""}}